Jack Henry & Associates, Inc.
162.55USD
+0.7500 (+0.46%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on JKHY.
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 2.1B | 2.2B | 2.4B | 2.5B | 2.7B | 2.9B |
| Q1 | 529.2M | 571.4M | 601.0M | 644.7M | 683.4M | — |
| Q2 | 505.3M | 545.7M | 573.8M | 619.3M | 658.1M | — |
| Q3 | 508.6M | 538.6M | 585.1M | 636.2M | — | — |
| Q4 | 534.6M* | 559.9M* | 615.4M* | 644.0M* | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 5.02 | 5.23 | 6.24 | 6.98 | 7.24 | 7.90 |
| Q1 | 1.46 | 1.39 | 1.63 | 1.97 | 2.01 | — |
| Q2 | 1.10 | 1.26 | 1.34 | 1.72 | 1.77 | — |
| Q3 | 1.12 | 1.19 | 1.52 | 1.71 | — | — |
| Q4 | 1.34* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| 1.38* |
| 1.75* |
| 1.54* |
| — |
| — |
Debt level and coverage